Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age

Abstract

The risk of birth and neurodevelopmental complications with prenatal exposure to antipsychotics is unclear.OBJECTIVE To evaluate the association between prenatal antipsychotics exposure and the risk of birth and neurodevelopmental problems. DESIGN, SETTING, AND PARTICIPANTSThis population-based cohort study included children born between January 2001 and January 2015 with follow-up to December 2019 who were identified by the Hong Kong Clinical Data Analysis and Reporting System. Pregnancies with maternal antidepressant/lithium exposure were removed. Primary analyses compared gestationally exposed and gestationally nonexposed individuals with propensity score fine stratification. Additional analyses included gestationally exposed individuals vs those with past exposure and a sibling-matched analysis to evaluate the effect of confounding by indication.EXPOSURES Prenatal antipsychotic exposure. MAIN OUTCOMES AND MEASURESPreterm birth (<37 gestational weeks), small for gestational age (birth weight <2 standard deviations below the mean for gestational age), and first diagnosis of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in children. RESULTSThe cohorts included 333 749 mother-child pairs for ADHD (mean [SD] maternal age at delivery, 31.46 [5.03] years) and 411 251 pairs for ASD, preterm birth, and small for gestational age analyses (mean [SD] maternal age at delivery, 31.56 [5.01] years). There were 13 196 children (3.95%) with a diagnosis of ADHD, 8715 (2.12%) with ASD, 33 891 (8.24%) preterm, and 7009 (1.70%) who were small for gestational age. The weighted hazard ratio (wHR) was 1.16 (95% CI, 0.83-1.61) for ADHD and 1.06 (95% CI, 0.70-1.60) for ASD, while the weighted odds ratio (wOR) was 1.40 (95% CI, 1.13-1.75) for preterm birth and 1.36 (95% CI, 0.86-2.14) for small for gestational age when comparing gestationally exposed with gestationally nonexposed individuals. Additional analyses showed no association when comparing gestationally exposed individuals with those with past exposure

Antipsychotic Use During Pregnancy and Risk for Gestational Diabetes: A National Register-Based Cohort Study in Sweden

“…The frequency of moderate to late prematurity was also increased amongst the women treated with antipsychotics before or after but not during the actual pregnancy. This is in line with the results of a study on antipsychotic use during pregnancy with a sibling analysis [ 53 ]. The risk increase for caesarean sections was clearly decreased when the women treated with antipsychotics were compared with the control group of women treated with antipsychotics before or after but not during the pregnancy.…”

Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia

“…Diagnostic ascertainment derived from CDARS has been used for patient identification and outcome identification in several high-quality pharmacoepidemiology studies for psychiatric disorders. 28 , 29 , 30 , 31 , 32 , 33 The present study was approved by the institutional review board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster. No informed consent was required because this was a register-based study using anonymized data.…”

Antidepressant use and risk of self-harm among people aged 40 years or older: A population-based cohort and self-controlled case series study

“…Population-based pharmaco-epidemiological studies have extensively validated the reliability of CDARS data. 18 , 19 , 20 …”